PubMed, Journal Year: 2024, Volume and Issue: 4(3), P. e935 - e935

Published: Dec. 1, 2024

Alzheimer's disease (AD) is the most frequent form of dementia and represents an increasing global burden, particularly in countries like Indonesia, where population has begun to age significantly. Current medications, including cholinesterase inhibitors NMDA receptor antagonists, have modest effects on clinical symptoms early middle stages, but there no curative treatment available so far despite progress. Activating or repressing epigenetic modifications, DNA methylation, histone modification microRNA regulation, appears play important role AD development. These alterations further enact transcriptional changes relevant signature pathologies amyloid-β deposition, tau protein malfunctioning, neuroinflammation, neuronal death. Here, we discuss feasibility targeting these as a new strategy due reversibility epigenetics their ability correct faulty gene expression. We also review combined promise stem cell therapies modulation neurodegeneration, inflammation cognitive decline. This approach may provide multifaceted slow progression, replace lost neurons, restore neural function. Despite challenges, ethical, financial, methodological barriers, ongoing research therapy holds for pioneering AD.

Language: Английский